Apelin: The Cardiovascular Peptide
Vasoactive Peptides
33 pmol/L EC50
Apelin activates cardiac contractility at picomolar concentrations, making it one of the most potent endogenous positive inotropic substances identified.
Szokodi et al., Circulation Research, 2002
Szokodi et al., Circulation Research, 2002
View as imageApelin is a peptide hormone discovered in 1998 that acts as the endogenous ligand for the APJ receptor, a G protein-coupled receptor expressed throughout the cardiovascular system. What makes apelin unusual among vasoactive peptides is its combination of effects: it simultaneously increases cardiac contractility, lowers blood pressure, and reduces the heart's workload, all without causing the hypertrophy that typically accompanies other positive inotropes.[1] This profile has made it one of the most studied cardiovascular peptide targets of the past two decades. For context on how apelin fits within the broader family of blood vessel-regulating peptides, see the adrenomedullin overview.
Key Takeaways
- Apelin activates cardiac contractility at an EC50 of 33 picomoles per liter, making it one of the most potent endogenous inotropes discovered (Szokodi et al., 2002)
- Chronic apelin infusion in mice increased cardiac output by 76% without causing cardiac hypertrophy (Ashley et al., 2005)
- In the first human study, systemic apelin infusion increased cardiac index and lowered blood pressure in both healthy subjects and heart failure patients (Japp et al., 2010)
- Unlike many vasodilators, apelin-mediated blood vessel relaxation was preserved in heart failure patients, suggesting the APJ pathway remains functional even in disease (Japp et al., 2010)
- Apelin-knockout mice develop progressive cardiac dysfunction with aging, indicating the peptide is required for normal heart maintenance (Kuba et al., 2007)
- Plasma apelin levels drop after myocardial infarction and correlate with disease severity, positioning apelin as both a biomarker and a therapeutic target (Weir et al., 2009)
Discovery and the APJ Receptor
The APJ receptor was first cloned in 1993 based on its structural similarity to the angiotensin II type 1 receptor (AT1R). Despite this resemblance, APJ does not bind angiotensin II, and it remained an orphan receptor for five years. In 1998, Tatemoto and colleagues isolated apelin from bovine stomach extracts, identifying it as the endogenous ligand that activates APJ.
Apelin is produced as a 77-amino acid preproprotein that is cleaved into several active forms: apelin-36, apelin-17, apelin-13, and the pyroglutamated form [Pyr1]apelin-13. The shorter forms tend to be more potent, with [Pyr1]apelin-13 showing the highest receptor binding affinity.[2]
The APJ receptor is expressed at high levels in the heart, blood vessels, kidneys, lungs, and specific brain regions, particularly the hypothalamus. This distribution pattern suggested cardiovascular significance long before the functional studies confirmed it. The receptor couples to Gi proteins (inhibiting cAMP) and also recruits beta-arrestin, and recent research has shown that these two signaling arms produce different cardiac effects: the Gi pathway mediates beneficial contractility, while beta-arrestin recruitment drives hypertrophy.
Cardiac Contractility: The Defining Discovery
The landmark finding that positioned apelin as a cardiovascular peptide of major interest came from Szokodi et al. in 2002.[3] Working with isolated perfused rat hearts, they showed that apelin infusion produced a dose-dependent increase in contractile force with an EC50 of just 33.1 picomoles per liter. To put this in perspective, this is active in the sub-nanomolar range, making apelin one of the most potent endogenous positive inotropic substances identified in any species.
The mechanism involves activation of phospholipase C (PLC) and protein kinase C (PKC), followed by stimulation of the sodium-hydrogen exchanger (NHE-1) and reverse-mode sodium-calcium exchange (NCX). This signaling cascade ultimately increases intracellular calcium availability to the contractile machinery without requiring increased L-type calcium current, a pathway distinct from that used by beta-adrenergic stimulation.
The same study found that apelin mRNA was markedly downregulated in two models of chronic ventricular pressure overload, the first hint that the apelin system might be disrupted in heart disease.
In Vivo Evidence: Stronger Heart Without Bigger Heart
Ashley et al. (2005) extended the Szokodi findings into living animals with a critical addition: they tested whether apelin's inotropic effects came with the hypertrophic cost that plagues other cardiac stimulants.[1]
Acute intraperitoneal apelin injection in mice decreased left ventricular end-diastolic area (from 0.122 to 0.104 cm², p = 0.006) while increasing ventricular elastance (from 3.7 to 6.5 mmHg/RVU, p = 0.018). These measurements indicate that the heart was contracting more forcefully while simultaneously being less distended, a hemodynamic profile clinicians describe as "unloading."
The chronic infusion data were even more striking. Over 14 days, apelin at 2 mg/kg/day increased velocity of circumferential shortening (from 5.36 to 6.85 circ/s, p = 0.049) and cardiac output (from 0.142 to 0.25 L/min, p = 0.001), a 76% increase. Post-mortem analysis revealed no increase in heart weight and no cellular hypertrophy. This combination of increased contractility without hypertrophy is exceptionally rare among inotropic agents and is the primary reason apelin attracted pharmaceutical interest for heart failure. ANP, another cardiac peptide, reduces loading through natriuresis rather than enhanced contractility, making the two systems complementary rather than redundant.
What Happens Without Apelin: Knockout Studies
Kuba et al. (2007) generated apelin gene-deficient mice and found that they developed progressive cardiac dysfunction with aging.[4] Young knockout mice appeared normal, but by middle age they showed reduced contractility, increased ventricular dimensions, and impaired response to pressure overload. When subjected to aortic banding (a model that mimics chronic hypertension), apelin-knockout mice progressed to heart failure more rapidly than their wild-type counterparts.
This finding established that apelin is not merely a pharmacological tool but a physiologically required component of normal cardiac maintenance. The progressive nature of the dysfunction suggests that the apelin-APJ system serves a tonic cardioprotective role throughout life.
Apelin in Human Heart Failure
Plasma levels as biomarker
Circulating apelin concentrations drop in heart failure. Goetze et al. (2006) proposed apelin as a plasma marker for cardiopulmonary disease, noting that levels inversely correlate with disease severity.[5] Weir et al. (2009) confirmed that plasma apelin concentration is acutely depressed following myocardial infarction, adding temporal specificity to the biomarker potential.[6] Sans-Roselló et al. (2017) went further, showing that low admission apelin levels in ST-elevation myocardial infarction patients had prognostic value for adverse outcomes.[7]
The pattern is consistent: the sicker the heart, the lower the apelin. Whether this reflects reduced production, increased degradation, or both remains under investigation. ACE2, the same enzyme relevant to SARS-CoV-2 entry, cleaves and partially inactivates both apelin-13 and apelin-17, adding complexity to the system's regulation.[8]
The first human cardiovascular trial
Japp et al. (2010) conducted the first randomized, double-blind, placebo-controlled study of apelin in humans.[9] The study involved 18 patients with NYHA class II-III chronic heart failure, 6 patients undergoing diagnostic coronary angiography, and 26 healthy volunteers.
Key findings from the human data:
Intrabrachial infusions of [Pyr1]apelin-13 caused forearm vasodilation in both patients and healthy controls (p < 0.0001). Critically, apelin-mediated vasodilation was preserved in heart failure patients (p = 0.3 for difference versus controls), while acetylcholine-mediated vasodilation was impaired (p = 0.01). This meant the APJ pathway remained functional in diseased hearts where other vasodilatory pathways had failed.
Intracoronary apelin-36 bolus increased coronary blood flow, raised the maximum rate of left ventricular pressure rise (a measure of contractility), and reduced both peak and end-diastolic left ventricular pressures (all p < 0.05).
Systemic infusions increased cardiac index and lowered mean arterial pressure and peripheral vascular resistance in both patients and controls (all p < 0.01). The heart rate increased only in controls, not in heart failure patients, suggesting the hemodynamic improvement was not driven by reflex tachycardia.
These results confirmed in humans what the animal data had suggested: apelin increases cardiac output while reducing the heart's workload. The preserved vasodilatory response in heart failure is particularly relevant because it suggests the APJ receptor could still be therapeutically targeted even in advanced disease where other systems have been downregulated.
The Apelin-ACE2 Connection
The relationship between apelin and ACE2 adds a layer of complexity that became relevant during the COVID-19 pandemic. Wang et al. (2016) demonstrated that ACE2 metabolizes and partially inactivates [Pyr1]apelin-13 and apelin-17, the two most physiologically active forms.[8] Kalea et al. (2010) reviewed the broader relationship between apelin and ACE2 in cardiovascular disease, noting that both systems are dysregulated in heart failure and may interact at multiple levels.[10]
This connection is relevant for two reasons. First, it means that the balance between apelin production and ACE2-mediated degradation determines the net apelinergic tone in the cardiovascular system. Second, conditions that alter ACE2 expression or activity, including SARS-CoV-2 infection and ACE inhibitor therapy, could indirectly affect the apelin system.
From Peptide to Drug: Development Challenges
Wysocka et al. (2018) reviewed the therapeutic landscape for apelin in cardiovascular diseases, obesity, and cancer.[11] Despite the compelling preclinical and early clinical data, bringing apelin-based therapies to patients faces several obstacles.
Native apelin peptides have short plasma half-lives, measured in minutes. Enzymatic degradation by ACE2, neprilysin, and other proteases limits their duration of action. This has driven development of modified analogs. Nyimanu et al. (2019) showed that apelin-36-[L28A] and a PEGylated variant improved diet-induced obesity in mice through G protein-biased signaling at the APJ receptor.[12] The emphasis on biased agonism reflects the discovery that Gi signaling provides cardiac benefits while beta-arrestin recruitment may cause detrimental hypertrophy.
Recent work published in Cell (2024) achieved a structure-based design of non-hypertrophic APJ receptor modulators, identifying compounds that maintain the Gi-mediated contractility enhancement while minimizing beta-arrestin-driven hypertrophy. Small molecule APJ agonists are also in development, which would avoid the stability issues inherent to peptide drugs.
The intersection of apelin and GLP-1 signaling has generated particular interest. Preclinical data evaluating APJ agonists in combination with GLP-1 receptor agonists suggest complementary cardiovascular benefits, with APJ agonism adding direct positive inotropy and vasodilation to GLP-1's metabolic and anti-inflammatory effects.
What the Evidence Supports and Where It Falls Short
The apelin-APJ system has a strong foundation: consistent animal data showing enhanced contractility without hypertrophy, one well-conducted human hemodynamic study confirming the key findings, and a clear biological rationale for heart failure therapy.
The limitations are equally clear. No apelin-based therapeutic has completed a phase III clinical trial. The human data comes from acute infusion studies, not chronic therapy. The inverted relationship between short- and long-form apelin variants, the complexity of biased signaling at the APJ receptor, and the modulation by ACE2 all create a drug development landscape that is mechanistically rich but clinically uncertain.
The Falcao-Pires et al. (2009) pulmonary hypertension study illustrates both the potential and the gap. They showed that apelin decreased myocardial injury and improved right ventricular function in a monocrotaline-induced pulmonary hypertension rat model, demonstrating that the peptide's benefits extend beyond the left ventricle to the pulmonary circulation.[13] But this finding remains confined to animal research, with no human pulmonary hypertension trials completed.
The sacubitril/valsartan story offers a relevant comparison. That drug combination, which works by boosting natriuretic peptides (a different family of cardiovascular peptides), took decades from initial peptide biology research to an approved heart failure treatment. Apelin-based therapies may follow a similar trajectory: the biology is established, the target is validated in humans, but the clinical development pathway stretches ahead.
Chandrasekaran et al. (2008) noted that while the apelin system's role in cardiovascular function is now established, translating this into a viable heart failure therapy requires solving the stability, selectivity, and chronic dosing challenges that have historically limited peptide drugs.[2] The move toward biased small-molecule agonists may ultimately be how this biology reaches patients, rather than the native peptide itself.
The Bottom Line
Apelin is among the most potent endogenous inotropes discovered, increasing cardiac contractility at picomolar concentrations while simultaneously reducing cardiac loading without hypertrophy. Human studies confirm these effects in both healthy volunteers and heart failure patients. Drug development is focused on biased agonists that preserve the beneficial Gi signaling while avoiding beta-arrestin-mediated hypertrophy, but no apelin-based therapy has yet completed late-stage clinical trials.